These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20157167)

  • 1. Cancer risk among patients with multiple sclerosis and their parents.
    Hofer S; Linnebank M; Weller M; Bahmanyar S; Montgomery SM; Hillert J; Ekbom A; Olsson T
    Neurology; 2010 Feb; 74(7):614-5; author reply 615. PubMed ID: 20157167
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer risk among patients with multiple sclerosis and their parents.
    Bahmanyar S; Montgomery SM; Hillert J; Ekbom A; Olsson T
    Neurology; 2009 Mar; 72(13):1170-7. PubMed ID: 19332695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
    Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
    Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
    Feigin PD
    Breast Cancer Res Treat; 2005 Jul; 92(2):197. PubMed ID: 15986130
    [No Abstract]   [Full Text] [Related]  

  • 5. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
    Achiron A; Miron S; Shoenfeld Y
    Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ocular side effects of drugs used in the treatment of multiple sclerosis].
    Santos-Bueso E; Serrador-García M; García-Sánchez J
    Arch Soc Esp Oftalmol; 2013 Dec; 88(12):493-5. PubMed ID: 24257261
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.
    Kümpfel T; Hoffmann LA; Pellkofer H; Pöllmann W; Feneberg W; Hohlfeld R; Lohse P
    Neurology; 2008 Nov; 71(22):1812-20. PubMed ID: 19029521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to farm crops, livestock, and farm tasks and risk of glioma: the Upper Midwest Health Study.
    Ruder AM; Carreón T; Butler MA; Calvert GM; Davis-King KE; Waters MA; Schulte PA; Mandel JS; Morton RF; Reding DJ; Rosenman KD;
    Am J Epidemiol; 2009 Jun; 169(12):1479-91. PubMed ID: 19403843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis poses tough drug development challenges.
    Senior K
    Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
    Sellebjerg FT; Sørensen PS;
    Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
    [No Abstract]   [Full Text] [Related]  

  • 11. Lead, genetic susceptibility, and risk of adult brain tumors.
    Rajaraman P; Stewart PA; Samet JM; Schwartz BS; Linet MS; Zahm SH; Rothman N; Yeager M; Fine HA; Black PM; Loeffler J; Shapiro WR; Selker RG; Inskip PD
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2514-20. PubMed ID: 17164378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer in first-degree relatives and risk of glioma in adults.
    Hill DA; Inskip PD; Shapiro WR; Selker RG; Fine HA; Black PM; Linet MS
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1443-8. PubMed ID: 14693735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis of multiple sclerosis: implications for treatment.
    Waldron-Lynch F; Hennessy MJ
    Ir Med J; 2004 Jan; 97(1):5-6. PubMed ID: 15055909
    [No Abstract]   [Full Text] [Related]  

  • 17. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy].
    García Merino A; Fernández O; Montalbán X; de Andrés C; Arbizu T
    Neurologia; 2010; 25(6):378-90. PubMed ID: 20738958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pragmatic approach to treatments in multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.